Chemoprevention in Inherited Colorectal Cancer Syndromes

Ophir Gilad, Charles Muller, Sonia S. Kupfer*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

Abstract

Cancer prevention in hereditary gastrointestinal predisposition syndromes relies primarily on intensive screening (e.g., colonoscopy) or prophylactic surgery (e.g., colectomy). The use of chemopreventive agents as an adjunct to these measures has long been studied both in the general population and in hereditary cancer patients, in whom the risk of malignancy, and therefore the potential risk reduction, is considerably greater. However, to date only few compounds have been found to be effective, safe, and tolerable for widespread use. Furthermore, many of the studies involving these rare syndromes suffer from small sample sizes, heterogeneous patient cohorts, short follow-up duration, and lack of standardized endpoints, creating challenges to draw generalizable conclusion regarding efficacy. The following review summarizes the current data on various chemopreventive compounds used in Lynch syndrome and familial adenomatous polyposis in addition to several agents that are currently being investigated.

Original languageEnglish (US)
Pages (from-to)172-179
Number of pages8
JournalClinics in Colon and Rectal Surgery
Volume37
Issue number3
DOIs
StatePublished - Apr 10 2024

Keywords

  • chemoprevention
  • familial adenomatous polyposis
  • Lynch syndrome

ASJC Scopus subject areas

  • Surgery
  • Gastroenterology

Fingerprint

Dive into the research topics of 'Chemoprevention in Inherited Colorectal Cancer Syndromes'. Together they form a unique fingerprint.

Cite this